|
|
|
|
| LEADER |
01453nam a2200229Ia 4500 |
| 001 |
10.1016-j.bbrc.2022.04.054 |
| 008 |
220706s2022 CNT 000 0 und d |
| 020 |
|
|
|a 0006291X (ISSN)
|
| 245 |
1 |
0 |
|a A novel self-assemble peptide drug design of AKT1 for anaplastic thyroid cancer therapy
|
| 260 |
|
0 |
|b Elsevier B.V.
|c 2022
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1016/j.bbrc.2022.04.054
|
| 520 |
3 |
|
|a Anaplastic thyroid cancer (ATC) is an undifferentiated subtype of thyroid cancer with a markedly poor survival prognosis, estimated to occur 3–5 months after diagnosis. Akt activation is reportedly involved in tumorigenesis during ATC and represents a new therapeutic target. Based on the Akt1/bisubstrate complex structure and artificial intelligence-assisted peptide drug screening, we designed a self-assemble Akt1-targeting peptide drug exhibiting a 0.89-nm structure and potential killing ability in ATC cells. The developed self-assemble Akt1-targeting peptide drug presented IC50 values of 18.2 μM and 12.4 μM in 8303C and 8505C cells, respectively, after 72 h of incubation. © 2022 The Authors
|
| 650 |
0 |
4 |
|a Akt1
|
| 650 |
0 |
4 |
|a Anaplastic thyroid cancer
|
| 650 |
0 |
4 |
|a Peptide drug
|
| 650 |
0 |
4 |
|a Self-assemble
|
| 700 |
1 |
0 |
|a Chai, L.
|e author
|
| 700 |
1 |
0 |
|a Li, R.
|e author
|
| 700 |
1 |
0 |
|a Qiu, Z.
|e author
|
| 700 |
1 |
0 |
|a Wang, K.
|e author
|
| 700 |
1 |
0 |
|a Zhang, X.
|e author
|
| 773 |
|
|
|t Biochemical and Biophysical Research Communications
|
